Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical, Cosmetic and Investigational Dermatology|March 26, 2011
Itch in psoriasis: epidemiology, clinical aspects and treatment optionsF Prignano, F Ricceri, L Pescitelli, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 31, 2009
Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbiditiesF Prignano, L Pescitelli, F Ricceri, et al.
The British Journal of Dermatology|March 8, 2011
Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patientsF Prignano, F Ricceri, L Pescitelli, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|February 15, 2011
A global approach to psoriatic patients through PASI score and Skindex-29F Prignano, G Ruffo, F Ricceri, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|August 13, 2011
Development of MGUS in psoriatic patients: a possible undiagnosed event during anti-TNF-α-treatmentF Prignano, L Pescitelli, F Ricceri, et al.
Dermatologic Therapy|February 7, 2013
Treatment of severe nail psoriasis with acitretin: an impressive therapeutic resultF Ricceri, L Pescitelli, L Tripo, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 20, 2019
Tuscan consensus on the diagnosis and treatment of hidradenitis suppurativaF Prignano, L Pescitelli, I Giani, et al.
International Journal of Clinical Pharmacy|January 6, 2019
Clinical experience with the etanercept biosimilar SB4 in psoriatic patientsL Pescitelli, L Lazzeri, A Di Cesare, et al.
Current Medical Research and Opinion|July 29, 2009
Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapiesF Prignano, F Ricceri, L Pescitelli, et al.
Archives of Dermatological Research|May 25, 2024
Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to-treat areasA Michelucci, F Manzo Margiotta, A Cartocci, et al.
Pageof 1